Based on Artificial intelligence, the web 3 DID platform GenomeFi announced the strategy partnership with Genomics on 15 April. Both Corporations will collaborate on Genome ecosystem expansion. The companies will expand their platform services, plan and launch genome-based products, and develop marketing strategies to attract domestic and global users. GenomeFI is a blockchain foundation that uses artificial intelligence analysis technology to build genetic big data. It strives to expand genome content and build an incentive system using blockchain technology. GenomeFi Foundation plans to launch a Genomic Decentralized Identity (GDID) service, which allows individual NFTs based on personal genetic information to be issued and used as an identity verification
Topics:
Live Bitcoin News considers the following as important: Press Release
This could be interesting, too:
Chainwire writes Nexo Unveils Strategic Rebrand as a Premier Digital Assets Wealth Platform
Chainwire writes Mawari Announces Node Sale to Bring Immersive Content to the World
Chainwire writes Serotonin Continues Global Expansion with the Opening of Serotonin Hong Kong
Chainwire writes Nozomi Introduces aATose: Ushering in the Era of Creator Sovereignty
Based on Artificial intelligence, the web 3 DID platform GenomeFi announced the strategy partnership with Genomics on 15 April.
Both Corporations will collaborate on Genome ecosystem expansion. The companies will expand their platform services, plan and launch genome-based products, and develop marketing strategies to attract domestic and global users.
GenomeFI is a blockchain foundation that uses artificial intelligence analysis technology to build genetic big data. It strives to expand genome content and build an incentive system using blockchain technology. GenomeFi Foundation plans to launch a Genomic Decentralized Identity (GDID) service, which allows individual NFTs based on personal genetic information to be issued and used as an identity verification tool by users
“Geromics is a bio specialist company that aims to solve extreme aging and diseases based on artificial intelligence and biotechnology. Recently, it signed a technology transfer agreement with Invitesgenomics about the seven technology patents related to the cancer vaccine platform “Neoantigen Cancer Vaccine Prediction Technology” and agreed to cooperate in developing personalized cancer vaccine therapies. Based on this, Geromics aims to develop and commercialize platform technologies to overcome aging and diseases in the long term.”
“Jimmy Choi, CEO of GenomeFi, said, ‘We plan to collaborate with excellent biotechnology companies and institutions to expand the bio ecosystem and popularize genome content.’ He added, ‘We will work together with Geromics not only for the expansion of the bio ecosystem but also for security and technical cooperation in all areas.”